Author

A. Jeyasekharan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. J. Kueh· 1 shared A. Karnezis· 1 shared A. S. Sedukhina· 1 shared A. Strasser· 1 shared A. T. Papenfuss· 1 shared A. Wei· 1 shared B. N. Pang· 1 shared C. Koenig· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Kueh

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genome-wide in vivo CRISPR screens identify GATOR1 as a potent tumor suppressor in MYC-driven lymphomagenesis

M. A. Potts, S. Mizutani, Y. Deng, S. Vaidyanathan, K. Ting, G. Giner, S. Shruti, Y. Liao, S. Diepstraten, A. J. Kueh, M. Pal, G. Healey, L. Tai, Z. Wang, C. Koenig, , M. J. Herold

The paper identifies GATOR1 as a tumor suppressor in MYC-driven lymphomagenesis using in vivo CRISPR screens and shows its sensitivity to mTOR inhibitors.

bioRxiv · Feb 16, 2022 · PreprintCancer Biology

Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51

M. M. Hoppe, T. Z. Tan, S. Lie, S. Lim, J. P. Yeong, J. D. Wardyn, P. Jaynes, D. G. Lim, B. N. Pang, A. Karnezis, D. Chiu, S. Leung, D. G. Huntsman, A. S. Sedukhina, K. Sato, , A. Jeyasekharan

This study shows that high RAD51 expression in ovarian cancer is linked to poor survival and platinum resistance, particularly in HRD-negative tumors, and correlates with immune exclusion.

bioRxiv · Jun 9, 2020Cancer Biology